<p>The Q4 earnings report for <strong>Exact Sciences</strong> (NASDAQ:EXAS) was released on Friday, February 13, 2026 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Exact Sciences missed estimated earnings by -362.5%, reporting an EPS of $-0.21 versus an estimate of $0.08.</p>
<p>Revenue was up $164.96 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.09, resulting in a 3.9% increase change in the share price the following day.</p>
<p>Here's a look at Exact Sciences's past performance:</p>
<p></p><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2025</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.15</td>
<td>0.02</td>
<td>-0.37</td>
<td>-0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.24</td>
<td>-0.01</td>
<td>-0.21</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>810.51M</td>
<td>774.43M</td>
<td>689.35M</td>
<td>701.30M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>850.74M</td>
<td>811.09M</td>
<td>706.78M</td>
<td>713.42M</td>
</tr>
</tbody>
</table><p></p>
<p>To track all earnings releases for Exact Sciences visit their earnings calendar here. </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>

ARKG

EXAS

<p>Exact Sciences (NASDAQ:EXAS) reported Q4 earnings on February 13, 2026, missing estimates by 362.5% with an EPS of $-0.21 against an expected $0.08. Revenue increased to $164.96 million compared to the previous year. In the prior quarter, the company exceeded EPS estimates by $0.09, leading to a 3.9% rise in share price. Historical performance shows fluctuations in EPS and revenue across previous quarters. For more details, visit their earnings calendar.</p>

benzinga_article

VanEck Biotech ETF

Ark Genomic Revolution ETF

Exact Sciences

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Genomics Immunology and Healthcare ETF

Health Care Select Sector SPDR

Exact Sciences Earnings Review: Q4 Summary